# US 11,896,645 B2 · Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,896,645 B2
- Document ID: US11896645B2
- Status: Granted
- Kind: B2
- Application number: 17/177,614
- Filed: 2021-02-17
- Published: 2021-06-10
- Granted: 2024-02-13
- Earliest claimed: 2015-11-05
- Assignees: University of the Witwatersrand, Johannesburg
- Applicants: University of the Witwatersrand, Johannesburg
- Inventors: Stefan Franz Thomas Weiss; Boitelo Theresiah Letsolo; Kerrilyn Naidoo; Tyrone Chad Otgaar
- Web page: https://patentgrep.com/patent/US11896645B2

## CPC

- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/06: Antipsoriatics
- A61P 19/10: for osteoporosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 35/04: specific for metastasis
- A61P 39/00: General protective or antinoxious agents
- C07K 14/70546: {Integrin superfamily}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2310/14: interfering nucleic acids [NA]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions, particularly wherein said telomere related diseases and/or telomere related medical conditions are cancer and cellular ageing. Particularly, herein is disclosed 37 kDa/67 kDa laminin receptor precursor/high affinity laminin receptor (LRP/LR) and/or a fragment thereof for use in the treatment and/or prevention of cellular ageing.

## Claims

### Claim 1

A method comprising: (a) transfecting a cell with a transfecting agent and (b) producing within the cell a 37 kDa/67 kDa laminin receptor precursor/high affinity laminin receptor (LRP/LR) comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2; wherein the level of human telomerase reverse transcription, telomerase activity, and/or telomere length is increased; and wherein the level of a senescent marker is decreased.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cell is from an animal, or a plant.

### Claim 3 (depends on 1)

The method of claim 1, wherein a senescent markers is selected from the group consisting of β-galactosidase, progerin, and H2AX foci.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cell is a HEK293 or MRC 5 cell.

### Claim 5 (depends on 1)

The method of claim 1, wherein the transfecting agent is a pClneo-LRP-FLAG plasmid.

### Claim 6 (depends on 5)

The method of claim 5, wherein the pClneo-LRP-FLAG plasmid comprises an amino acid sequence of SEQ ID NO: 3.